Psychopharmacology and mental retardation: A 10 year review (1990-1999)

Research in Developmental Disabilities

Volumn 21, Issue 4, 2000, Pages 263-296

  Matson, Johnny L ^a   Bamburg, Jay W ^a   Mayville, Erik A ^a   Pinkston, Jim ^a   Bielecki, Joanne ^a   Kuhn, David ^a   Smalls, Yemonja ^a   Logan, James R ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Pinecrest Developmental Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZATROPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLONIDINE; CLORAZEPATE; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LEVOTHYROXINE; LITHIUM; MESORIDAZINE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROPRANOLOL; RISPERIDONE; SERTRALINE; THIORIDAZINE; TIOTIXENE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VERAPAMIL;

ANXIETY NEUROSIS; ARTICLE; AUTISM; BEHAVIOR DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEEDING DISORDER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERACTIVITY; MEDICAL LITERATURE; MENTAL DEFICIENCY; MENTAL HEALTH CARE; NEUROTOXICITY; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; STEREOTYPY; TIC; TREATMENT OUTCOME;

AGGRESSION; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MENTAL DISORDERS; MENTAL RETARDATION; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOPHARMACOLOGY; SELF-INJURIOUS BEHAVIOR;

EID: 0034622204     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-4222(00)00042-1     Document Type: Article

References (82)

1. Aman M.G., Singh N.N. Pharmacological intervention. Matson J.L., Mulick J.A. Handbook of Mental Retardation. 1983;Pergamon, New York.
2. Aman M.G., Richmond G., Stewart A.W., Bell J.C., Kissell R. The Aberrant Behavior Checklist Factor structure and the effect of subject variables in American and New Zealand facilities . American Journal of Mental Deficiency. 91:1987;570-578.
3. Aman M.G., Teehan C.J., White A.J., Turbott S.H. Haloperidol treatment with chronically medicated residents Dose effects on clinical behavior and reinforcement contingencies . American Journal on Mental Retardation. 93:1989;452-460.
4. Diagnostic and Statistical Manual-Fourth Edition. 1994;APA, Washington D.C.
5. The American Psychological Association Code of Ethics, Standard 6.05b. 1992;APA, Washington D.C.
6. Barak Y., Ring A., Levy D., Granek I., Szor H., Elizur A. Disabling compulsions in 11 mentally retarded adults An open trial of clomipramine . Journal of Clinical Psychiatry. 56:1995;459-461.
7. Barnhill J., Carlos A. Phenobarbital-induced disinhibition in the developmentally disabled. Case report. Journal of Clinical Psychopharmacology. 17:1997;229-230.
8. Baroff G.S. Mental Retardation Nature, cause, and management . 1974;John Wiley & Sons, New York.
9. Baumeister A.A., Sevin J.A. Pharmacologic control of aberrant behavior in the mentally retarded Toward a more rational approach . Neuroscience & Biobehavioral Reviews. 14:1990;253-262.
10. Baumeister A.A., Todd M.E., Sevin J.A. Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation. Clinical Neuropharmacology. 16:1993;271-294.
11. Beale I.L., Smith O.A., Webster D.M. Effects of chlorpromazine and thioridazine on discrimination learning in children with mental retardation. Journal of Developmental and Physical Disabilities. 5:1993;43-54.
12. Benjamin E., Bout-Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome. Journal of the American Academy of Child and Adolescent Psychiatry. 32:1993;870-873.
13. Benjamin S., Seek A., Tresise L., Price E., Gagnon M. Case study Paradoxical response to naltrexone treatment of self-injurious behavior . Journal of the American Academy of Child and Adolescent Psychiatry. 34:1995;238-242.
14. Bodfish J.W., Madison J.T. Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation. American Journal on Mental Retardation. 98:1993;360-367.
15. Borthwick-Duffy S.A. Epidemiology and prevalence of psychopathology in people with mental retardation. Journal of Consulting and Clinical Psychology. 62:1994;17-27.
16. Brasic J.R., Barnett J.Y. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Psychological Reports. 80:1997;163-170.
17. Brasic J.R., Barnett J.Y., Kaplan D., Sheitman B.B., Aisemberg P., Lafargue R.T., Kowalik S., Clark A., Tsaltas M.O., Young J.G. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 44:1994;1309-1312.
18. Buzan R.D., Dubovsky S.L., Treadway J.T., Thomas M. Opiate antagonists for recurrent self-injurious behavior in three mentally retarded adults. Psychiatric Services. 46:1995;511-512.
19. Campbell M., Anderson L.T., Small A.M., Adams P., Gonzales N.M., Ernst M. Naltrexone in autistic children Behavioral symptoms and attentional learning . Journal of the American Academy of Child and Adolescent Psychiatry. 32:1993;1283-1290.
20. Carpenter M., Cowart C.A., McCallum R.S., Bell S.M. Effects of antipsychotic medication on discrimination learning for institutionalized adults who have mental retardation. Behavioral Residential Treatment. 5:1990;105-120.
21. Cohen S.A., Ihrig K., Lott R.S., Kerrick J.M. Risperidone for aggression and self-injurious behavior in adults with mental retardation. Journal of Autism and Developmental Disorders. 28:1998;229-233.
22. Cook E.H., Rowlett R., Jaselskis C., Leventhal B.L. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry. 31:1992;739-745.
23. Crews W.D., Bonaventura S., Rowe F.B. Cessation of long-term naltrexone for self-injury A case study . Research in Developmental Disabilities. 14:1993;331-340.
24. Dartnall N.A., Holmes J.P., Morgan S.N., McDougle C.J. Brief report Two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism . Journal of Autism and Developmental Disorders. 29:1999;87-91.
25. Davanzo P.A., Belin T.R., Widawski M.H., Bryan H.K. Paroxetine treatment of aggression and self-injury in persons with mental retardation. American Journal on Mental Retardation. 102:1998;427-437.
26. Dent J. Catatonic syndrome following recovery from neuroleptic malignant syndrome. Journal of Intellectual Disability Research. 39:1995;457-459.
27. Diaz S.F. Mania associated with risperidone use. Journal of Clinical Psychiatry. 57:1996;41-42.
28. Fisher W., Piazza C.C., Page T.J. Assessing independent and interactive effects of behavioral and pharmacologic interventions for a client with dual diagnoses. Journal of Behavior Therapy and Experimental Psychiatry. 20:1989;241-250.
29. Garber H.J., Mcgonigle J.J., Slomka G.T., Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. Journal of the American Academy of Child and Adolescent Psychiatry. 31:1992;1157-1160.
30. Garcia D., Smith R.G. Using analog baselines to assess the effects of naltrexone on self-injurious behavior. Research in Developmental Disabilities. 20:1999;1-21.
31. Gedye A. Neuroleptic induced dementia documented in four adults with mental retardation. Mental Retardation. 36:1998;182-186.
32. Ghaziuddin M., Tsai L.Y., Ghaziuddin N. Haloperidol treatment of trichotillomania in a boy with autism and mental retardation. Journal of Autism and Developmental Disorders. 21:1991;365-371.
33. Ghaziuddin M., Tsai L., Ghaziudden N. Fluoxetine in autism with depression. Journal of the American Academy of Child and Adolescent Psychiatry. 30:1991;508-509.
34. Gordon C.T., Rapoport J.L., Hamburger S.D., State R.C., Mannheim G.B. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry. 149:1992;363-366.
35. Gross E.J., Hull H.G., Lytton G.J., Hill J.A., Piersel W.C. Case study of neuroleptic induced akithisia Important implications for individuals with mental retardation . American Journal on Mental Retardation. 98:1993;156-164.
36. Hammock R.G., Schroeder S.S., Levine W.R. The effect of clozapine on self-injurious behavior. Journal of Autism and Developmental Disorders. 25:1995;611-626.
37. Hanzel T.E., Kalachnik J.E., Harder S.R. A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. Research in Developmental Disabilities. 13:1992;381-392.
38. Hardan A., Johnson K., Johnson C., Hrecznyj B. Case study Risperidone treatment of children and adolescents with developmental disorders . Journal of the American Academy of Child and Adolescent Psychiatry. 35:1996;1551-1556.
39. Hellings J.A., Kelley L.A., Gabrielli W.F., Kilgore E., Shah P. Sertraline response in adults with mental retardatio and autistic disorder. Journal of Clinical Psychiatry. 57:1996;333-336.
40. Hill B.K., Balow E.A., Bruininks R.H. A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacology Bulletin. 21:1985;279-284.
41. Hilton D.K., Martin C.A., Heffron W.M., Hall B.D. Imipramine treatment of ADHD in a Fragile X child. Journal of the American Academy of Child and Adolescent Psychiatry. 30:1991;831-834.
42. Horrigan J.P., Barnhill L.J. Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorders. 27:1997;313-323.
43. Horrigan J.P., Barnhill L.J., Courvoisie H.E. Olanzapine in PDD. Journal of the American Academy of Child and Adolescent Psychiatry. 36:1997;1166.
44. Howland R.H. Chlorpromazine and obsessive-compulsive symptoms. American Journal of Psychiatry. 153:1996;1503-1504.
45. Kahn B.U. Brief report Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults . Journal of Autism and Developmental Disorders. 27:1997;479-489.
46. Kastner T., Friedman D.L. Verapamil and valproic acid treatment of prolonged mania. Journal of the American Academy of Child and Adolescent Psychiatry. 31:1992;271-275.
47. Kastner T., Friedman D.L., Pond W.S. Carbamazepine-induced hyponatremia in patients with mental retardation. American Journal on Mental Retardation. 96:1992;536-540.
48. Lakin K.C., Hill B.K., Hauber F.A., Bruininks R.H., Heal L.W. New admissions and readmissions to a national sample of public residential facilities. American Journal on Mental Retardation. 88:1983;13-20.
49. Langee H.R., Conlon M. Predictors of responses to antidepressant medicatons. American Journal on Mental Retardation. 97:1992;65-70.
50. Lewis M.H., Bodfish J.W., Powell S.B., Golden R.N. Clomipramine treatment for stereotypy and related repetitive movement disorders associated with mental retardation. American Journal on Mental Retardation. 100:1995;299-312.
51. Lewis M.H., Bodfish J.W., Powell S.B., Parker D.E., Golden R.N. Clomipramine treatment for self-injurious behavior of individuals with mental retardation A double blind comparison with placebo . American Journal on Mental Retardation. 6:1996;654-665.
52. May P., London E.B., Zimmerman T., Thompson R. The study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Annals of Clinical Psychiatry. 7:1995;155-160.
53. McDougle C.J., Brodkin E.S., Yeung P.P., Naylor S.T., Cohen D.J., Price L.H. Risperidone in adults with autism or pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology. 5:1995;273-282.
54. McDougle C.J., Holmes J.P., Bronson M.R., Anderson G.M., Volkmar F.R., Price L.H., Cohen D.J. Risperidone treatment of children and adolescents with pervasive developmental disorders A prospective, open-label study . Journal of the American Academy of Child and Adolescent Psychiatry. 36:1997;685-693.
55. McDougle C.J., Holmes J.P., Carlson D.C., Pelton G.H., Cohen D.J., Price L.H. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry. 55:1998;633-641.
56. Myers B.A., Pueschel S.M. Brief report A case of schizophrenia in a population with Down syndrome . Journal of Autism and Developmental Disorders. 24:1994;95-98.
57. Natarajan D., Martin A.J., Tesh D. Risperidone therapy in the control of behavioural disturbances in patients with learning disability. Irish Journal of Psychiatric Medicine. 14:1997;69-71.
58. Nicholson R., Awad G., Sloman L. An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry. 37:1998;372-376.
59. Percy A.K., Glaze D.G., Schultz R.J., Zoghbi H.Y., Williamson D., Frost J.D. Jr, Jankovic J.J., del Junco D., Skender M., Waring S., Meyer E.C. Rett syndrome Controlled study of an oral opiate antagonist, naltrexone . Annals of Neurology. 35:1994;464-470.
60. Potenza M.C., Holmes J.P., Kanes S.J., McDougle C.J. Olanzapine treatment of children, adolescents, and adults with Pervasive Developmental Disorders An open-label pilot study . Journal of Clinical Psychopharmacology. 19:1999;37-44.
61. Purdon S.E., Lit W., Labelle A., Jones B.D.W. Risperidone in the treatment of Pervasive Developmental Disorder. Canadian Journal of Psychiatry. 39:1994;400-405.
62. Reese R.M. Biobehavioral analysis of self-injurious behavior in a person with profound handicaps. Focus on Autism and Other Developmental Disorders. 12:1997;87-94.
63. Ricketts R.W., Goza A.B., Ellis C.R., Singh Y.N. Clinical effects of buspirone on intractable self-injury in adults with mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry. 33:1994;270-276.
64. Ricketts R.W., Goza A.B., Ellis C.R., Singh Y.N., Singh N.N., Cooke J.C. Fluoxetine treatment of severe self-injury in young adults with mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry. 32:1993;865-869.
65. Rosenquist P.B., Bodfish J.W., Thompson R. Tourette syndrome associated with mental retardation A single subject treatment study with haloperidol . American Journal on Mental Retardation. 101:1997;497-504.
66. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatric Annals. 27:1997;219-221.
67. Ruedrich S.L., Grush L., Wilson J. Beta andranergic blocking medications for aggressive and self-injurious mentally retarded persons. American Journal on Mental Retardation. 95:1990;110-119.
68. Sandman C.A., Barron J.L., Colman H. An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior. American Journal on Mental Retardation. 95:1990;93-102.
69. Sandman C.A., Hetrick W., Taylor D.V., Chicz-DeMet A. Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. American Journal on Mental Retardation. 102:1997;182-199.
70. Scotti J.R., Evans I.M., Meyer L.H., Walker P. A metanalysis of intervention research with problem behavior Treatment validity and standards of practice . American Journal on Mental Retardation. 96:1991;233-256.
71. Scotti J.R., Schulman D.E., Hojnacki R.M. Functional analysis and unsuccessful treatment of Tourette's syndrome in a man with profound mental retardation. Behavior Therapy. 25:1994;721-738.
72. Singh N.N., Ellis C.R., Crews D.W., Singh Y.N. Does diminished dopaminergic neurotransmission increase pica? Journal of Child and Adolescent Psychopharmacology. 4:1995;93-99.
73. Singh N.N., Landrum T.J., Ellis C.R., Donatelli L.S. Effects of thioridazine and visual screening on stereotypy and social behavior in individuals with mental retardation. Research in Developmental Disabilities. 14:1993;163-177.
74. Sovner R., Hurley A. The management of chronic behavior disorders in mentally retarded adults with lithium carbonate. Journal of Nervous and Mental Disturbance. 169:1981;191-195.
75. Sperner U.B., Czeipek I., Gaggl S., Geissler D., Speil G., Fleischhacker W.W. Treatment of severe clozapine induced neutropenia with granulocyte colony stimulating factor (G-CSF) Remission despite continuous treatment with clozapine . British Journal of Psychiatry. 172:1998;82-84.
76. Suzuki E., Knba S., Nibuya M., Shintani F. Use of pimozide in the Pisa syndrome. American Journal of Psychiatry. 149:1992;1114-1115.
77. Taylor D.V., Hetrick W.P., Neri C.L., Touchette N.P., Barron J.L., Sandman C.A. Effect of naltrexone upon self-injurious behavior, learning, and activity A case study . Pharmacology Biochemistry and Behavior. 40:1991;79-82.
78. Thompson T., Hackenberg T., Cerutti D., Baker D., Axtell S. Opioid antagonist effects on self-injury in adults with mental retardation Response for and location as determinants of medication effects . American Journal on Mental Retardation. 99:1994;85-102.
79. Vanden Borre R., Vermote R., Buttiens M., Thiry P., Dierick G., Geutjens J., Sieben G., Heylen S. Risperidone as add-on therapy in behavioural disturbances in mental retardation a double-blind placebo-controlled cross-over study . Acta Psychiatrica Scandinavica. 87:1993;167-171.
80. Walters A.S., Barrett R.P., Feinstein C., Mercurio A., Hole W.T. A case report of naltrexone treatment of self-injury and social withdrawal in autism. Journal of Autism and Developmental Disorders. 20:1990;169-176.
81. Williemsen-Swinkels S.H.N., Buitelaar J.K., Nijhof G.J., van Engeland H. Failure of naltrexone hydrocholoride to reduce self-injurious and autistic behavior in mentally retarded adults. Archives in General Psychiatry. 52:1995;766-773.
82. Zarkowska E., Crawley B., Locke J. A behavioural intervention for Gilles de la Tourette syndrome in a severely mentally handicapped girl. Journal of Mental Deficiency Research. 33:1989;245-253.